Proton Pump Inhibitors in Cirrhotic Patients

National Liver Institute, Egypt1,000 enrolled

Overview

Proton pump inhibitors (PPIs) inappropriate use, in patients with cirrhosis, presents a significant clinical challenge. This study evaluates overprescription and misuse of PPIs in cirrhotic patients. The patterns of use of PPIs will be classified into two groups based on adherence to the proven indications: Group A: Inappropriate use of PPI, Group B: Appropriate use of PPI. We will estimate the prevalence of PPI misuse in cirrhotics and correlate it with different factors.

The inappropriate use of PPIs in cirrhosis patients is a growing concern. Evidence supporting the use of PPIs in cirrhosis-related conditions is limited. Several adverse outcomes have been linked to PPI use in cirrhosis, including an increased risk of spontaneous bacterial peritonitis and hepatic encephalopathy. The study aimed to assess the appropriateness of prescribing PPIs to patients with cirrhosis, examining its impact on prescribing practices and identifying associated factors. in this observational, descriptive, cross-sectional study, cirrhotic patients receiving proton pump inhibitors will be included in the study. Enrolled patients will classified according to the indication for PPI administration: Group A: Inappropriate use of PPI, Group B: Appropriate use of PPI. Use of PPI will be considered inappropriate when prescribed without approved indication or used for a prolonged period beyond the recommended duration. The prevalence of PPI misuse in cirrhotics will be estimated and multivariate analyses will be conducted in order to identify independent predictors of inappropriate use of PPI.

Study Type

OBSERVATIONAL

Enrollment

1,000

Conditions

Proton Pump Inhibitor Adverse Reaction Liver Cirrhosis

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients receiving proton pump inhibitors at the time of enrollment. Exclusion Criteria: * Refusal to sign the informed consent form or failure to provide the required information

Locations (1)

National Liver institute - Menoufia University

Shibīn al Kawm, Menoufia, Egypt

Outcomes

Primary Outcomes

Inappropriate use of PPIs

Explore the prevalence of using PPIs without approved indication or for a prolonged period beyond the recommended duration in patients with liver cirrhosis

Time frame: Six weeks after study completion

Predictors for inappropriate use of PPIs

Determine independent predictors of inappropriate use of PPIs in patients with liver cirrhosis using multivariate analyses.

Time frame: Eight weeks after study completion

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.